Immix Biopharma (IMMX) Assets Average (2022 - 2026)

Immix Biopharma has disclosed Assets Average across 5 years of filings, most recently posting $100.3 million for Q1 2026.

• Assets Average for Q1 2026 came in at $100.3 million, up 368.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.3 million (up 368.39% YoY), and the FY2025 annual result was $63.9 million, up 198.06% from the prior year.
• Assets Average came in at $100.3 million for Q1 2026 at Immix Biopharma, up from $62.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $100.3 million in Q1 2026 to a low of $14.1 million in Q1 2023.
• The 5-year median for Assets Average is $19.6 million (2022), against an average of $27.7 million.
• Across the five-year window, Assets Average sank 43.77% in 2025 and soared 368.39% in 2026, its largest moves.
• Immix Biopharma's Assets Average stood at $16.2 million in 2022, then surged by 31.26% to $21.2 million in 2023, then increased by 13.42% to $24.0 million in 2024, then jumped by 159.77% to $62.5 million in 2025, then surged by 60.63% to $100.3 million in 2026.
• The last three Assets Average figures came in at $100.3 million (Q1 2026), $62.5 million (Q4 2025), and $17.9 million (Q3 2025), per Business Quant data.